Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

Rid­ing on the mo­men­tum of two li­cens­ing deals, Har­bour Bio­Med now has $85 mil­lion to ad­vance its fresh­ly beefed up pipeline.

GIC — Sin­ga­pore’s sov­er­eign wealth fund — led the Se­ries B, lead­ing a syn­di­cate that in­cludes Chi­na Life Pri­vate Eq­ui­ty In­vest­ment and Ver­tex Ven­tures as well as Se­ries A in­vestors Ad­van­Tech and Leg­end Cap­i­tal.

Founder and CEO Jing­song Wang calls the round a “strong vote of con­fi­dence” for the Chi­nese biotech’s three-pronged strat­e­gy built around its foun­da­tion­al hu­man trans­genic an­ti­body tech­nol­o­gy, dubbed Har­bour Mice: out-li­cens­ing its tech, in-li­cens­ing as­sets to de­vel­op on the plat­form and dis­cov­er­ing new ones in-house.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.